Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Key Highlights
- ➤Jupiter Neurosciences (JUNS) doses first patient in Phase 2a RESET Parkinson’s trial
- ➤RESET plans approximately 30 patients across two JOTROL doses and placebo
- ➤Jupiter retains Tungsten Advisors to explore strategic options and transactions
- ➤Strategic options may include asset sales, licensing, partnerships, or business combinations
- ➤JOTROL Phase 1 showed increased resveratrol exposure and measurable cerebrospinal fluid concentrations
Expert Statements
Christer Rosén, Chief Executive Officer of Jupiter Neurosciences
“Dosing the first patient in RESET is a significant milestone for Jupiter and the culmination of years of scientific, regulatory and clinical development work”
Christer Rosén, Chief Executive Officer of Jupiter Neurosciences
“We believe that JOTROL has the potential to address biological pathways implicated in Parkinson’s disease, including mitochondrial dysfunction, oxidative stress and neuroinflammation.”
Christer Rosén, Chief Executive Officer of Jupiter Neurosciences
“With patient dosing now underway, we look forward to advancing enrollment and generating clinical data that will help us evaluate JOTROL’s potential in this significant area of unmet medical need.”
Fernando L. Pagan, Principal Investigator; professor of neurology at Georgetown University School of Medicine and Vice Chairman of the Department of Neurology
“The first patient dosed in RESET represents an important step in translating the scientific rationale for JOTROL into a clinical study in people living with Parkinson’s disease”
Fernando L. Pagan, Principal Investigator; professor of neurology at Georgetown University School of Medicine and Vice Chairman of the Department of Neurology
“This study is designed to provide important information regarding JOTROL’s safety, pharmacokinetics and biological activity in Parkinson’s disease and to help inform the future clinical development of the program.”
Alison Silva, President and Chief Business Officer of Jupiter Neurosciences
“Moving from enrollment to dosing our first patient is a defining moment for Jupiter and, importantly, puts us in a position to begin generating patient data from our lead clinical program”
Alison Silva, President and Chief Business Officer of Jupiter Neurosciences
“We remain focused on efficient execution of the study and look forward to providing updates as the program progresses.”
First Patient Dosed with JOTROL(™) Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL(™) in Patients with Parkinson’s Disease
Tungsten Advisors has been retained to identify strategic options to monetize Jupiter’s existing clinical development programs via corporate partners and explore other strategic options for a transaction to maximize shareholder value
Get started
Create a free account to read the full story.